Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2b trial to assess the correlation of the biomarker measurements with the clinical benefit-risk of RX-3117 in patients with pancreatic cancer or non-small cell lung cancer

Next Previous
Trial Profile

A phase 2b trial to assess the correlation of the biomarker measurements with the clinical benefit-risk of RX-3117 in patients with pancreatic cancer or non-small cell lung cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roducitabine (Primary)
  • Indications Non-small cell lung cancer; Pancreatic cancer
  • Focus Therapeutic Use

Most Recent Events

  • 29 Nov 2023 According to Processa Pharmaceuticals media release, discussion with the FDA to determine Phase 2b/3a study design expected in the first half of 2024
  • 28 Jun 2021 New trial record
  • 17 Jun 2021 According to a Processa Pharmaceuticals media release, this trial is expected to begin in 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top